Getting the GIST of long non-coding RNA

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, often driven by KIT or PDGFRA mutations.
• Imatinib is the standard treatment for advanced GIST, but secondary resistance develops in over half of patients.
• Long non-coding RNAs (lncRNAs) are emerging as key regulators of gene expression in GIST, impacting disease progression and treatment response.

Purpose of the Study:

• To provide a comprehensive review of the current knowledge on lncRNAs in GIST.
• To elucidate the roles of lncRNAs in GIST pathogenesis, progression, and imatinib resistance.
• To explore the clinical potential of lncRNAs as prognostic/predictive biomarkers and therapeutic targets.

Main Methods:

• Literature review of studies on lncRNAs in GIST.
• Analysis of lncRNA functions as oncogenes or tumor suppressors in GIST.
• Evaluation of lncRNAs' role in imatinib resistance mechanisms.

Main Results:

• lncRNAs are involved in complex gene expression regulation in GIST.
• Specific lncRNAs can function as oncogenes or tumor suppressors, influencing GIST behavior.
• lncRNAs are implicated in the development of secondary resistance to imatinib.

Conclusions:

• lncRNAs offer valuable insights into GIST biology and resistance mechanisms.
• lncRNAs hold potential as prognostic and predictive indicators in GIST patients.
• Targeting lncRNAs presents a promising avenue for novel GIST therapeutic strategies.